Editors’ pickHealth

FDA OKs Accurian Nerve Ablation Platform for Chronic Pain

The US Food and Drug Administration (FDA) has approved Medtronic’s Accurian system that provides radiofrequency (RF) ablation of nerve tissue to reduce chronic pain, the company announced.

RF ablation is a minimally invasive procedure in which current produced by radio waves destroys small areas of nerve tissue to stop it from sending pain signals, thereby reducing pain, the company explains in a news release.

The Accurian RF ablation system was designed for “consistency and efficiency,” Marshall Stanton, MD, senior vice president and president of Medtronic’s pain therapies division, says in the release.

The RF ablation system uses proprietary hardware and advanced software to control power and temperature resulting in consistent and predictable lesion formation. The system can perform standard, pulsed, and enhanced procedures to generate a range of lesion shapes, sizes, and volumes.

It has been extensively tested for lasting reliability and is upgrade-ready as technology advances, the company says.

“The Accurian RF ablation platform is a significant addition in my practice because I know I’ll get the same lesion every time in every channel due to how responsive the generator is in managing power and temperature,” Leo Kapural, MD, PhD, a pain physician at Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, says in the release.

“RF ablation requires both precision and flexibility. Accurian is intuitive and easy to use and enables me to easily upgrade the system and perform enhanced lesions with cooled RF probes,” he adds.

The FDA previously approved Medtronic’s Intellis spinal cord stimulation implant for chronic intractable pain, as reported by Medscape Medical News.

For more Medscape Neurology news, join us on Facebook and Twitter.

Source link

Back to top button
Thanks !

Thanks for sharing this, you are awesome !

Pin It on Pinterest

Share This

Share this post with your friends!